NRXP vs XENE
NRXP: Clinical-stage biotech developing ketamine and NMDA receptor-modulating drugs for treatment-resistant depression, PTSD, and suicidal ideation with three candidates in late-stage FDA review. XENE: A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and depression.
Side-by-side fundamentals
| Metric | NRXP | XENE | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.63 | $65.78 | |
| Market cap as of 2026-07-29 | $148M | $6.4B | |
| PEG as of 2026-07-29 | n/a | -0.30 | |
| Net margin as of 2026-07-29 | -2336.5% | -867.3% | XENE higher |
| Gross margin as of 2026-07-29 | +58.8% | n/a | |
| Operating margin as of 2026-07-29 | -1830.6% | -969.8% | XENE higher |
| ROE as of 2026-07-29 | -195.8% | -49.2% | XENE higher |
| ROA as of 2026-07-29 | -219.6% | -46.4% | XENE higher |
| Debt / equity as of 2026-07-29 | 1.42 | 0.00 | XENE lower |
| Revenue growth (YoY) as of 2026-07-29 | n/a | -7.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -77.8% | |
| Beta as of 2026-07-29 | 2.16 | 0.62 | |
| 1-year return as of 2026-07-27 close | +21.0% | +117.1% | XENE higher |
Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.